Clough Capital Partners L P Purchases New Holdings in TransMedics Group, Inc. $TMDX

Clough Capital Partners L P purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 7,119 shares of the company’s stock, valued at approximately $866,000.

Other large investors also recently bought and sold shares of the company. Kensington Investment Counsel LLC bought a new stake in TransMedics Group during the 3rd quarter valued at about $1,926,000. Fieldview Capital Management LLC bought a new stake in TransMedics Group during the 3rd quarter valued at about $1,716,000. Citigroup Inc. increased its stake in TransMedics Group by 29.3% during the 3rd quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock valued at $8,615,000 after purchasing an additional 17,414 shares in the last quarter. Fred Alger Management LLC increased its stake in TransMedics Group by 303.8% during the 3rd quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock valued at $16,913,000 after purchasing an additional 113,408 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in TransMedics Group by 78.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 47,048 shares of the company’s stock valued at $5,279,000 after purchasing an additional 20,750 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Piper Sandler reduced their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. TD Cowen reduced their price objective on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $134.00.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $73.22 on Thursday. The company has a 50 day moving average price of $84.57 and a 200-day moving average price of $113.51. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The firm has a market capitalization of $2.53 billion, a PE ratio of 16.64 and a beta of 1.91. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business’s revenue was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.70 earnings per share. As a group, equities research analysts expect that TransMedics Group, Inc. will post 1.98 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.